Lung Cancer Trials Ask AI to find trials
UnknownNot applicableNCT05635266
Official study title

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Study summary

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSpecimen sample

The study team can explain what participation involves.

Who it may be forAge-Related Macular Degeneration · Allergies

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 7, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Sanguine Biosciences

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Sanguine Biosciences
Interventions being studied
Diagnostic Test: Specimen sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Persons 18 to 85 years of age at the date of informed consent.
  • If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting.
  • Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.
Reasons someone may not be able to joinExclusion criteria
  • Persons younger than 18 years of age or older than 85 years of age at the date of informed consent.
  • Receipt of blood products 30 days before the study blood draw.
  • Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
  • A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks.
  • Has donated a unit of blood within the last 2 months at the date of informed consent.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Sanguine BiosciencesWaltham, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 7, 2024. Always confirm current availability with the study team.

View original record ↗